SBRA Company Profile and Key Details

SBRA has shown sold momentum, gaining 3.54% over the past week and 8.88% over the past quarter, though year-to-date performance is up 3.54%. Short-term trend indicators are bearishly aligned (SMA20 1.47%, SMA50 2.31%, SMA200 5.13%). The stock’s 14-day RSI is 55.29 (neutral), while the ATR of 0.39 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -3.46% below its high and over 23.63% above its low. Average 10-day trading volume of 2.76 million shares is in line with the 3-month average of 2.77 million, indicating normal recent market interest.

Sabra Health Care REIT, Inc. (NASDAQ:SBRA) closed at $19.28 USD, losing -$0.33 (-1.68%) from the previous close of $19.61. The stock is currently within 5% of its 52-week high $15.60 and $19.97. With a market capitalization of about $4.59 billion, Sabra Health Care REIT, Inc. is classified as a mid-cap and shows lower-than-market volatility (beta ~0.66). Key stats such as the average daily volume over the past year has been around 2.85 million shares, volume is running light vs its 52-week average. Headquartered in Irvine, CA, Sabra Health Care REIT, Inc. operates in the Real Estate sector and the REIT - Healthcare Facilities industry. Led by CEO Richard K. Matros, the company employs approximately 50 people and listed since April 02, 2002. As of March 31, 2022, Sabra's investment portfolio included 416 real estate properties held for investment.

Sabra Health Care REIT, Inc. has 239.79 million shares outstanding. The public float is 235.93 million shares, elevated short interest at 10.61% of float. This equals 18.07 million shares. The short ratio is 7.03 days. Institutional investors hold 99.95% of the float. Insiders own 1.24%. MATROS RICHARD K holds 959.99 thousand shares, Andrews Harold W. Jr. has 474.69 thousand shares and Costa Michael Lourenco has 183.22 thousand shares.

Sabra Health Care REIT, Inc. generated EPS of $0.73 over the past year. Five-year average earnings growth is 7.91%. Wall Street analysts project EPS growth of 13.88% annually over the next five years. The latest quarter delivered EPS of $0.09. The next quarter is forecast at $0.17. Next year's EPS is expected at $400.00. Analyst sentiment is neutral. Analyst rating data shows there are 5 Strong Buy ratings, 0 Buy ratings, 7 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $22.00 to $17.00. The high target offers 14.11% upside. The low target suggests -11.83% downside. The mean target is $20.08. This offers 4.15% upside. Sabra Health Care REIT, Inc. earnings surprise history is a mixed track record. The quarter that ended November 05, 2025, missed forecasts by -76.32%. The prior quarter beat by 2.7%. Over the last six quarters, Apple has recorded several small beats. These include -71.43% in August 07, 2024.

Sabra Health Care REIT, Inc. last paid a dividend of 1.2 per share, this equals a trailing yield of roughly 7.55%. Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $50.58. This means the shares are trading below this model’s fair value.

Sabra Health Care REIT, Inc. trades at a P/E ratio of 25.16, slightly below the S&P 500 average, with a price-to-sales ratio of 6.26 and a price-to-book ratio of 1.69 suggesting the stock is closer to book value. The P/FCF stands at 13.55, also above market averages.

Sabra Health Care REIT, Inc. (NASDAQ:SBRA) shares are flat 3.54% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Sabra Health Care REIT, Inc. trading at a premium to the broader market with a P/E of 25.16. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $16.99, suggesting -11.88% downside. Our AI forecast model points to short-term strength (5.29% over two weeks), a medium-term fall (-2.18% over three months), and a longer-term gain (10.48% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Sabra Health Care REIT, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 5.29%, with price expected at $20.30 by January 23, 2026, within a range of $20.02 to $20.58 3-Month Outlook: Projected fall of -2.18%, reaching $18.86 by April 09, 2026, with a range of $18.66 to $19.08. 1-Year Outlook: Projected gain of 10.48%, with price at $21.30 by December 31, 2026, within a range of $20.92 to $21.68.